Evidence map›Paper›PMID 40192165›Full record

ArticleChembiochem : a European journal of chemical biology2025

Inhibition of Surfactin Biosynthesis in Bacillus Subtilis Using Cell-Permeable Adenylation Domain Inhibitors.

Fumihiro Ishikawa, Sho Konno, Hideaki Kakeya, Genzoh Tanabe

Abstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fumihiro IshikawaFaculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-osaka, Osaka, 577-8502, Japan.ORCID https://orcid.org/0000-0002-8681-9396
Sho KonnoDepartment of System Chemotherapy and Molecular Sciences, Division of Medicinal Frontier Sciences, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo, Kyoto, 606-8501, Japan.ORCID https://orcid.org/0000-0002-5851-4130
Hideaki KakeyaDepartment of System Chemotherapy and Molecular Sciences, Division of Medicinal Frontier Sciences, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo, Kyoto, 606-8501, Japan.
Genzoh TanabeFaculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-osaka, Osaka, 577-8502, Japan.ORCID https://orcid.org/0000-0002-7954-8874

Funding

Anti-aging Project for Private UniversitiesGrant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology 17H06401Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology 19H02840Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology 22H04901Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology 23H04882Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology 24H00493Institute Foundation for Science, Osaka (IFO)Japan Foundation for Applied EnzymologyKindai University Research Enhancement Grant IP003Research Foundation for Pharmaceutical SciencesUehara Memorial Foundation
6 · The paper itself

Abstract

Several natural bacterial virulence factors are biosynthesized by nonribosomal peptide synthetases (NRPSs). Therefore, NRPSs producing such natural products have emerged as attractive antibiotic targets. N-(aminoacyl)sulfamoyladenosine (aminoacyl-AMS) derivatives with chemical modifications at 2'-OH group of the adenosine skeleton are previously reported that inhibit NRPS amino acid adenylation (A) domains in recombinant enzyme systems, cellular lysates, and bacterial cells. The introduction of a couple of functionalities at the 2'-OH group preserves the binding affinity toward NRPS amino acid A-domains and improves cell permeability of the AMS scaffold. However, the effects of these compounds on secondary metabolism have not yet been explored. In this study, an affinity-based protein profiling (AfBPP) probe, L-Leu-AMS-BPyne, is validated for in-cell applications, including imaging of NRPS activities in bacteria. Next, L-Leu-AMS derivatives incorporating methyl, benzyl, and cyanomethyl functionalities at the 2'-OH group are synthesized and their inhibitory activity toward intracellular surfactin-NRPSs in the surfactin-producer Bacillus subtilis ATCC 21332 are investigated using the AfBPP probe. Finally, the attenuation of surfactin production using a Leu-AMS-BPyne probe and L-Leu-AMS derivatives in B. subtilis is demonstrated. These results indicate that chemical modifications at the 2'-OH group provide a way to develop cell-permeable and functional NRPS A-domain inhibitors.

Indexed as

Anti-Bacterial AgentsBacillus subtilisLipopeptidesPeptides, CyclicPeptide SynthasesBacterial ProteinsProtein DomainsAnti-Bacterial AgentsBacterial ProteinsLipopeptidesnon-ribosomal peptide synthasePeptides, CyclicPeptide Synthasessurfactin peptideadenylation domainsinhibitor cell permeabilitynonribosomal peptide synthetasestRNA synthetase inhibitorsvirulence factors

Identifiers

PMID40192165
PMCPMC12177696

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.